June 16, 2014 — Boston Scientific Corp. has initiated the RESPOND post-market registry to assess real-world performance of the Lotus valve system. The RESPOND registry will collect data on clinical outcomes and device performance in 1,000 patients implanted at 50 centers around the world.


June 16, 2014 — Children with heart disease are exposed to low levels of radiation during X-rays, which do not significantly raise their lifetime cancer risk. However, children who undergo repeated complex imaging tests that deliver higher doses of radiation may have a slightly increased lifetime risk of cancer, according to researchers at Duke Medicine. The findings, published June 9 in the American Heart Association (AHA) journal Circulation, represent the largest study of cumulative radiation doses in children with heart disease and associated predictions of lifetime cancer risk.

Medtronic announced it is purchasing Covidien in a cash-and-stock deal for $42.9 billion. Once the transaction is completed, Medtronic will have significantly advanced its position as a premier international medical technology and services company. 

Cardinal Health announced the 2 millionth shipment of the Mynx Vascular Closure Device (VCD).

MedAptus announced First Coast Cardiovascular Institute (FCCI) is live on the company's Professional Charge Capture (Pro) application and is already experiencing significantly reduced charge lag just weeks after installation.


June 12, 2014 — Three-dimensional imaging known as 3-D quantitative coronary angiography (3D-QCA) accurately identifies hard-to-see coronary artery lesions that merit further evaluation, according to the IQ-CATEGORIZE Lesions study presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2014 scientific sessions in Las Vegas.

The U.S. Food and Drug Administration (FDA) today expanded the indicated use for the CoreValve self-expanding transcatheter aortic valve system for patients with severe aortic stenosis who are at high risk for surgery. CoreValve originally gained FDA clearance in January for patients at extreme risk for surgical valve replacement. This new approval is based on groundbreaking data that showed clinical outcomes at one year with the CoreValve system were superior to the current gold standard of open-heart surgery.

June 12, 2014 — Philips Healthcare recently introduced Vereos PET/CT, the first digital PET/CT (positron emission tomography/computed tomography) scanner, at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis. In addition to Vereos, Philips showcased a selection of molecular imaging solutions designed to deliver high image quality, critical clinical information and greater connectivity.

Ischemic heart disease, a narrowing of the arteries supplying blood to the heart, is a leading cause of death throughout the world. A hybrid molecular imaging technique called positron emission tomography and magnetic resonance (PET/MR) imaging, which tells doctors vital information about cardiac and arterial function, has been found to be an effective molecular imaging tool for detecting coronary artery disease (CAD), say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now